Prescription drugs and opioids on table top viewing up close.
The federal 340B drug pricing program is failing to meet the needs of the vulnerable patients the program was intended to serve, while raising health care costs for employers and families, according to a new white paper.
“The 340B program is raising health care expenses for employer-sponsored health plans by $5.2 billion annually through the loss of rebates,” said Ilyse Schuman, senior vice president, health and paid leave policy, for the American Benefits Council. “But the costs don’t end there. Exponential growth of the program is also fueling hospital and provider consolidation, which further contributes to health cost inflation, and promoting increased use of higher-cost therapies.”
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
